CGEM News and Press, Cullinan Oncology Inc.

2026-03-10 07:30:02 ET More on Cullinan Therapeutics Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Cullinan Therapeutics: Cash-Ri...

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of ...

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

Cullinan Therapeutics Inc. (CGEM) is expected to report $-0.8 for Q4 2025

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced its parti...

2026-02-23 17:39:15 ET Shares of Cullinan Therapeutics ( CGEM ) have risen by 31% year-to-date, yet are down 70% over the past five years.... Read the full article on Seeking Alpha For further details see: Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engag...

2026-02-19 16:05:00 ET Cullinan Therapeutics, Inc. (CGEM) Citi's 2026 Virtual Oncology Leadership Summit February 19, 2026 10:00 AM EST... Read the full article on Seeking Alpha For further details see: Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncol...

CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadi...

2026-02-17 06:15:08 ET Citigroup analyst issues BUY recommendation for CGEM on February 17, 2026 10:58AM ET. CGEM was trading at $11.59 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 8 - Buy recommendati...